First Trust Advisors LP Increases Stock Position in argenex SE $ARGX

First Trust Advisors LP boosted its position in shares of argenex SE (NASDAQ:ARGX) by 98.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 107,195 shares of the company’s stock after acquiring an additional 53,293 shares during the period. First Trust Advisors LP’s holdings in argenex were worth $78,279,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of ARGX. M&T Bank Corp grew its holdings in argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after purchasing an additional 774,916 shares during the period. Sands Capital Management LLC raised its holdings in argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after acquiring an additional 340,245 shares during the last quarter. Invesco Ltd. boosted its stake in argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares during the last quarter. Wellington Management Group LLP grew its holdings in argenex by 80.1% in the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares in the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of argenex by 570.3% in the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after acquiring an additional 250,278 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the topic of several analyst reports. Royal Bank Of Canada lifted their price target on argenex from $945.00 to $1,025.00 and gave the stock an “outperform” rating in a report on Friday. Wells Fargo & Company increased their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a report on Monday, June 1st. Bank of America raised their price objective on argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Citigroup lifted their target price on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, argenex has a consensus rating of “Moderate Buy” and a consensus target price of $1,050.50.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

argenex Trading Down 0.7%

argenex stock opened at $918.22 on Friday. The company has a fifty day simple moving average of $868.28 and a 200-day simple moving average of $815.12. The stock has a market cap of $57.44 billion, a P/E ratio of 35.26, a price-to-earnings-growth ratio of 1.14 and a beta of 0.45. argenex SE has a 12-month low of $587.37 and a 12-month high of $953.58.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, topping analysts’ consensus estimates of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analysts’ expectations of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 70.27%. As a group, sell-side analysts forecast that argenex SE will post 26.27 earnings per share for the current fiscal year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.